Unmet Need: Reliable biomarker and therapeutic targets for androgen-independent prostate cancer
Prostate cancer (PC) is the second most common cause of cancer related deaths in men in the United States. PC is initially androgen-dependent, making androgen deprivation therapy (ADT) the first line of defense in combating the disease. Though this treatment initially reduces tumor size, almost all patients eventually develop androgen-independent prostate cancer (AIPC), which is resistant to this primary form of therapy and is ultimately lethal.
The Technology: Late stage prostate cancer diagnostic and therapeutic
Researchers at WSU have identified several previously unreported genes associated with prostate cancer and its progression to an androgen independent state. The expression levels of these identified genes can be used to determine the disease state of prostate cancer, whether it has or is progressing to an androgen-independent state. Currently there are limited options for the treatment of prostate cancer once it has progressed to this state. The ability to quickly diagnose the stage of disease progression aids in the implementation of the correct therapy in a timely manner. In addition, researchers have shown that RNAi knockdown of a critical gene significantly reduces androgen-independent growth which could greatly improve current treatment options once the disease state has progressed to this difficult-to treat androgen-independent stage. Also, a subset of the identified genes provide, as another biomarker, significant detection ability of prostate cancer recurrence after a prostatectomy.
• To determine the state of progression of androgen-dependent to androgen-independent prostate cancer via gene biomarker and treating the later stage of prostate cancer via suppression of gene biomarker
• Novel biomarker for the determination of the disease state of prostate cancer, specifically the ability to identify when it is progressing or has progressed to an androgen-independent state
• RNAi knockdown of an identified gene leads to significant reduction of the rate of androgen-independent growth – currently this stage is nearly untreatable
• A subset of identified genes can be used as a biomarker for the determination of prostate cancer recurrence after a prostatectomy
US national stage patent application filed: https://www.google.com/patents/US20170183739?cl=en